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OBJECTIVE
Little is known about the impact of diabetes self-management behavior (SMB) on
long-term outcomes. We aimed to examine the association among patient-
reported SMB, intermediate clinical outcomes, andmortality in patients with type
2 diabetes.
RESEARCH DESIGN AND METHODS
Data were collected from 340 patients with type 2 diabetes of the KORA-A study
(1997/1998) whowere recruited from two previous population-based surveys (n =
161) and a myocardial infarction registry (n = 179) in southern Germany. Based on
previousmethodological work, a high level of SMBwas defined as being compliant
with at least four of six different self-care dimensions, comprising physical exer-
cise, foot care, blood glucose self-monitoring, weight monitoring, having a diet
plan, and keeping a diabetes diary. The vital status of the participants was ob-
served until 2009. Multivariable linear, logistic, and Cox regression models were
applied to assess the association with intermediate clinical outcomes at baseline
and to predict mortality over the follow-up period, adjusted for sociodemo-
graphic, behavioral, and disease-related factors.
RESULTS
In the cross-sectional perspective, a high level of SMB was weakly associated
with a lower glycated hemoglobin A1c level (20.44% [24.8 mmol/mol] [95% CI
20.88 to 0.00]), but not with low-density lipoprotein cholesterol, systolic blood
pressure, or the presence of microalbuminuria, peripheral arterial disease, or
polyneuropathy. During a mean follow-up time of 11.6 years, 189 patients died.
SMB was a preventive factor for all-cause (hazard ratio 0.61 [95% CI 0.40–0.91])
and cardiovascular mortality (0.65 [95% CI 0.41–1.03]).
CONCLUSIONS
Although measuring SMB is difficult and the used operationalization might be
limited, our results give some indication that a high level of SMB is associated
with prolonged life expectancy in patients with type 2 diabetes and highlight the
potential impact of the patients’ active contribution on the long-term trajectory of
the disease. We assume that the used proxy for SMB is associated with unmea-
sured, but important, dimensions of health behavior.
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Diabetes mellitus is a chronic metabolic
disorder and major public health prob-
lem that is associated with an increased
risk of microvascular and macrovascular
complications, premature death, re-
duced quality of life, and significantly
increased health care costs (1–3). Follow-
ing the predictions of the International
Diabetes Federation (4) regarding future
diabetes incidence, the medical and eco-
nomic burden of the disease will in-
crease further, resulting in an urgent
need for efficient preventive and cura-
tive strategies.
With the St. Vincent Declaration in
1989, for the first time European coun-
tries formulated strategic targets and
action plans to improve the quality of
diabetes care, to enhance patients’
self-management, and ultimately to re-
duce diabetes-related complications
(5). Reinforced by a vast body of re-
search showing that intensive drug
therapy, appropriate risk factor control,
and screening for diabetes-related com-
plications are cost-effective interven-
tions to reduce the burden of diabetes,
great efforts have been made to in-
crease the quality of diabetes care
(6–8). Although routine care often still
falls short of reaching targeted goals,
there is some evidence that the imple-
mentation of evidence-based treat-
ment guidelines and structured disease
management programs has improved
the quality of care on a large-scale basis
(9,10).
As themajor part of day-to-day care is
handled by the patients themselves, it is
assumed that self-management behav-
ior (SMB) is an important andmodifiable
element in the disease management
process that is crucial in determining
health outcomes (11,12). Reflected by
the multidimensional practice of activi-
ties that patients initiate on their own to
maintain health, self-management is
seen as a context-dependent health re-
source depending on individual needs,
goals, and priorities, as well as on med-
ical recommendations (13,14). Previous
cross-sectional studies predominantly
identified factors that are associated
with self-care activities, such as socio-
economic status, sex, and diabetes educa-
tion, but rarely investigated associations
between SMB and health outcomes
(15–17). Results from randomized trials
have shown that self-management ed-
ucation moderately improved self-care
and SMB, as well as short-term glycemic
control; however, the sustainability of
these effects over time has not yet
been studied (18,19). To the best of
our knowledge, also only a few obser-
vational studies have analyzed the asso-
ciation between single dimensions of
SMB, such as self-monitoring of blood
glucose (SMBG) and mortality (20,21),
but none has yet examined this relation-
ship by accounting for the multidimen-
sional character of patient SMB. The
lack of studies targeting this important
research question might be related to
the fact that despite methodological ef-
forts in the development of approaches
to assess self-management, measuring
this highly individualized and complex
construct has proved to be difficult.
Therefore, current instruments often
focus on specific self-care activities
and behaviors, such as blood glucose
self-monitoring, foot care, or physical
activity, that are assumed to be univer-
sally important for all patients with di-
abetes (15,16,22–24). One approach
to define SMB has been proposed by
Arnold-Wörner et al. (15), who tested a
multidimensional compliance index in a
population-based sample of patients
with type 2 diabetes.
The objectives of this study are, first,
to analyze the cross-sectional associa-
tion between diabetes SMB and inter-
mediate clinical health outcomes at
baseline, and, second, to examine the
predictive value of SMB on mortality
by linking the self-management index
of Arnold-Wörner et al. (15) with data
from a 12-year mortality follow-up.
RESEARCH DESIGN AND METHODS
Data Source
The datawere taken from thepopulation-
based KORA-A study (Cooperative Health
Research in the Region of Augsburg). For
the KORA-A study (1997/1998, n =
1,002), all subjects from two previous
population-based MONICA/KORA sur-
veys (S2, S3) and from the MONICA/
KORA Myocardial Infarction Registry
with a physician-validated diagnosis of
diabetes were invited, together with
sex- and age-stratified nondiabetes
matches. The MONICA/KORA surveys
S2 (1989/1990, participation rate
76.9%) and S3 (1994/1995, participa-
tion rate 74.9%) were part of the multi-
national World Health Organization
MONICA project and included 4,940
and 4,856 noninstitutionalized inhabi-
tants, respectively, aged 25–74 years
living in the city of Augsburg and two
surrounding counties in southern Ger-
many. In theMONICA/KORAMyocardial
Infarction Registry, all hospitalized
cases of acute myocardial infarction
(MI) among subjects aged 25–74 years
from the same study area have been
registered since 1985. The study design,
sampling methods, and measurement
procedures of the KORA/MONICA stud-
ies and the registry have been described
in detail elsewhere (25,26). The KORA-A
survey was conducted in 1997/1998,
and included a standardized interview
assessing socioeconomic characteris-
tics, risk factors, and medical history; a
comprehensive questionnaire incorpo-
rating questions about received diabe-
tes care and self-care behavior; an
assessment of medication; and a physi-
cal examination including blood and
urine samples. The participation rate
of subjects with diabetes was 61.7%
for those from the surveys and 71.4%
for those from the Myocardial Infarc-
tion Registry. The survival status of all
subjects was observed until 2009. All
participants gave written informed con-
sent, and the study was granted full eth-
ical approval by the ethics commission
of the Bavarian Medical Association.
Measures
SMB at Baseline
SMB was defined by a multidimensional
“compliance index,” which was devel-
oped and tested in a previous study
(15) on the same sample of patients us-
ing self-reported information from the
interview and questionnaire. This com-
pliance index comprises the following
six different dimensions: performing
regular physical exercise (at least 60
min/week), conducting regular foot
care (checking for wounds at least
once per week), SMBG (at least once a
day for patients treated with insulin and
at least twice a week for others), moni-
toring of body weight (at least once a
week) in the last 6 months prior to ex-
amination, as well as currently keeping
a diabetes diary and having a diet plan.
According to this index, having a high
level of SMB is defined as being compli-
ant, that is, achieving the level of action
in the referred time period with at least
four out of six dimensions. The develop-
ment and the properties of this index
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have been described in detail elsewhere
(15).
Intermediate Clinical Outcomes at Baseline
Parallel to the collection of data about
SMB, established screening tests were per-
formed todetectmicroalbuminuria, defined
by a urine albumin-to-creatinine ratio of
$30 mg/g (albumin: immunoturbidimetric
test, Tina-quant; creatinine: enzymatic
colorimetric test, Boehringer Mannheim);
polyneuropathy, defined by a Michigan
Neuropathy Screening Instrument score
of .2; as well as peripheral arterial dis-
ease (PAD), defined by an ankle–brachial
index of,0.9 (Mini Dopplex device; HNE
Huntleigh Nesbit Evans Healthcare).
Also, glycatedhemoglobinA1c (HbA1c; im-
munologic test kit, Tina-quant; Boehringer
Mannheim) and LDL (enzymatic method,
cholesterol oxidase/p-aminophenazone,
Boehringer Mannheim) concentrations
were obtained from nonfasting venous
blood samples, and systolic blood pres-
sure was assessed as the average of the
second and third of three measurements
obtained from patients while in a sitting
position (random zero sphygmomanom-
eter; Hawksley & Sons Ltd.).
Mortality Over the Follow-up Period
The vitality status of all participants was
assessed in a mortality follow-up con-
ducted between October 2008 and De-
cember 2009. Information was obtained
by address search and by contacting the
regional registration authorities. There
were only 26 participants with a shorter
follow-up time. The mean follow-up
time until censoring was 11.6 years.
The underlying cause of death was ob-
tained from death certificates and was
classified into all-cause mortality (ICD-9
code 001–999) and cardiovascular dis-
ease (CVD) mortality (ICD-9 codes 390–
459, 798).
Covariates Assessed at Baseline
Sociodemographic characteristics, in-
cluding sex, age (in years), and educa-
tion (primary education, #9 years of
school; secondary/tertiary education,
.9 years of school); as well as infor-
mation about treatment regimen (diet
and lifestyle only, oral antidiabetic
drugs, insulin); diabetes duration (in
years); smoking status (smoker/ex-
smoker vs. never-smoker); objectively
assessed weight status (normal weight,
BMI ,25 kg/m2; overweight, BMI $25
and ,30 kg/m2; obesity, BMI $30
kg/m2); and self-reported history of
MI, stroke, retinopathy, neuropathy,
and nephropathy (kidney insufficiency
or dialyses) were retrieved from the in-
terview, the questionnaire, and the
physical examinations.
To assess medication, patients were
asked to bring the original packaging of
the pharmaceutical products taken dur-
ing the last 7 days prior to the exam-
ination. Based on this information,
Anatomical Therapeutic Chemical Clas-
sification System codeswere assigned to
define the use of antihypertensive med-
ication (C02–C04 and C07–C09), lipid-
lowering medication (C10), and aspirin
and nonaspirin antiplatelet medication
(B01AC06 and N02BA01, and B01AC and
B01AB).
Statistical Analysis
Descriptive statistics of the baseline
characteristics are reported for the en-
tire sample and also separately for
patients with high and low levels of di-
abetes SMB. Differences in the charac-
teristics between these two groups
were tested by ANOVA for continuous
variables, and by x2 tests for categori-
cal variables.
To analyze the cross-sectional associa-
tion between diabetes self-management
and intermediate clinical outcomes at
baseline, logistic regression models were
applied for binary outcomes and ordinary
least-squares regression models for con-
tinuous outcomes. These models were
adjusted for a basic set of covariates in-
cluding sociodemographic variables, se-
verity of diabetes, history of disease,
and, in a second step, also formedication.
Using the same sets of covariates,
multivariate Cox proportional hazards
regression was applied to predict all-
cause mortality and CVD mortality over
the follow-up period according to the
baseline level of SMB. The proportional
hazards assumption was tested using
the Kolmogorov-type supremum test.
In each model, covariates violating the
proportional hazards assumption were
introduced as time-covariate inter-
actions. To detect possible effect modi-
fiers in the survival models, all two-way
interactions between the basic set of
covariates and the self-management
variable were tested. Except for educa-
tion, none was significant at a 5% level.
Accordingly, Cox models were finalized
without interaction terms, but separate
models were calculated for subpopula-
tions with high or low levels of education.
In a final step, models were also adjusted
for intermediate clinical outcomes (mi-
croalbuminuria, polyneuropathy, PAD,
HbA1c, LDL cholesterol, and systolic blood
pressure).
To account for the great importance
of CVD comorbidity among diabetes pa-
tients and to avoid potential bias related
to themethodological property of the self-
management index, in which the thresh-
old for blood glucose self-monitoring
depends on the treatment status, all mod-
els were in addition stratified for CVD co-
morbidity (previous MI or stroke vs. no
CVD event) and treatment status (insulin-
treated vs. not insulin-treated).
In order to avoid power reduction re-
lated to the multivariate adjustment of
models, we applied a Markov chain
Monte Carlo method to impute missing
covariates.We performed single instead
of multiple imputations because of the
relatively low percentage of missing val-
ues and the high computational effort
associated with analyzing models based
onmultiple imputed data sets. To assess
the sensitivity of the results to missing
data, we refitted a random sample of
the models with a multiple imputation
approach. Further, we performed de-
tailed analyses for each of the six self-
management dimensions and applied
Cox regression models using the cumu-
lative number of compliant dimensions
instead of the predefined dichotomized
self-management index.
RESULTS
Characteristics of the Study
Population
From the 397 participants who an-
swered the diabetes questionnaire,
367 were identified as having type 2 di-
abetes (surveys, n = 172; Myocardial In-
farction Registry, n = 195). According
to the self-management index, 66 of
these study subjects reported having a
high level of SMB ($4 compliant self-
management dimensions), whereas
274 subjects were categorized as
having a low level of SMB. Because of
missing values, no categorization was
possible for 27 study subjects. The
characteristics of the sample at baseline
(1997/1998, n = 340) according to lev-
el of diabetes self-management are
shown in Table 1. The mean age was
67.2 years. Some70%of the study subjects
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were male, 89% were either overweight
or obese, and approximately one-third
of subjects reported insulin intake. In to-
tal, 60% of the participants already had
experienced a cardiovascular event (MI
or stroke).
Cross-sectional Association
Between SMB and Intermediate Clinical
Outcomes
The adjusted odds ratios (ORs) of a pos-
itive screening for microalbuminuria
(prevalence 48%), polyneuropathy
(prevalence 33%), and PAD (prevalence
20%) according to the level of self-
management are depicted in Table 2. In
general, the likelihood of these outcomes
was slightly lower for patients with a high
level of SMB compared with those with a
low level of SMB (ORs between 0.65 and
0.88); however, none of the revealed as-
sociations was statistically significant.
Table 2 further shows the adjusted
mean differences concerning HbA1c
(mean 7.1%), LDL cholesterol (134
mg/dL), and systolic blood pressure
(143 mmHg) from multivariate ordinary
least-squares regression models. Study
subjects with a high level of SMB had a
borderline significantly better HbA1c
value (mean difference 20.44% [24.8
mmol/mol] [95% CI 20.88 to 0.00])
than their less compliant counterparts.
LDL cholesterol and systolic blood
pressure levels did not differ signifi-
cantly between patients with good or
poor self-management. The additional
adjustment for medication (see model 3)
had hardly any effect in both the logistic
and the linear regression models.
Association Between SMB and
Mortality
In total, 189 of the 340 patients (56%)
died, 148 (44%) from CVD. The adjusted
hazard ratios (HRs) for all-cause and CVD
mortality are illustrated in Table 3.
All-Cause Mortality
Controlling for a basic set of covariates,
diabetes patients with high level of SMB
had a 39% reduced risk of dying (HR 0.61
[95% CI 0.40–0.91]). This effect ap-
peared to be robust after controlling
for antihypertensive, lipid-lowering,
Table 1—Sample characteristics at baseline (1997/1998) stratified by the level of SMB
Variables
Self-management index
P valueAll (N = 340)
High level of SMB
(n = 66)
Low level of SMB
(n = 274)
Age, mean (SD), years 67.2 (8.2) 65.1 (8.3) 67.7 (8.1) 0.017*
Diabetes duration, mean (SD), years 13.5 (9.5) 14.7 (8.8) 13.3 (9.7) 0.257*
Sex 0.856†
Men 239 (70.3) 47 (71.2) 192 (70.1)
Women 101 (29.7) 19 (28.8) 82 (29.9)
Education 0.180†
Primary 253 (74.6) 45 (68.2) 208 (76.2)
Secondary 86 (25.4) 21 31.8 65 23.8
Treatment 0.063†
Diet 47 (13.8) 4 (6.1) 42 (15.4)
Oral medication 175 (51.5) 33 (50.0) 141 (51.8)
Insulin 118 (34.7) 29 (43.9) 89 (32.7)
Weight status 0.764†
Normal weight 35 (10.8) 7 (11.3) 28 (10.7)
Overweight 154 (47.7) 27 (43.6) 127 (48.7)
Obese 134 (41.5) 28 (45.2) 106 (40.6)
Smoker (vs. never smoker) 205 (60.3) 41 (62.1) 163 (59.9) 0.735†
Macrovascular events
MI 195 (57.4) 40 (60.6) 153 (56.3) 0.552†
Stroke 33 (9.7) 7 (10.6) 26 (9.6) 0.783†
Microvascular complications
Nephropathy 9 (3.3) 0 (0) 9 (4.1) 0.216‡
Retinopathy 55 (19.5) 13 (24.5) 42 (18.4) 0.306†
Neuropathy 41 (12.2) 12 (18.5) 29 (10.8) 0.088†
Medication
Antihypertensive agents 255 (75.0) 48 (72.7) 207 (75.6) 0.635†
Lipid-lowering agents 67 (19.7) 13 (19.7) 54 (19.7) 0.998†
Antiplatelet agents 196 (57.7) 39 (59.1) 156 (56.9) 0.791†
Compliant dimensions of
self-management index
Exercising 85 (25.0) 32 (48.5) 53 (19.3) ,0.001†
Foot care 156 (46.6) 58 (89.2) 98 (36.3) ,0.001†
SMBG 95 (27.9) 48 (72.7) 47 (17.2) ,0.001†
Weight monitoring 204 (60.4) 64 (98.5) 140 (51.3) ,0.001†
Diet plan 127 (39.1) 43 (68.3) 84 (32.1) ,0.001†
Diabetes diary 85 (26.1) 43 (67.2) 42 (16.0) ,0.001†
Values are given as n (%), unless otherwise stated. *ANOVA. †x2 test. ‡Fisher exact test.
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and antiplatelet medication in model 2,
as well as after additional adjustment
for intermediate clinical outcomes in
model 3 (0.62 [0.41–0.94]).
CVD Mortality
Similar but nonsignificant effects were
observed for CVD mortality. A high level
of self-management was associated
with a 35% reduced hazard of dying
from any CVD cause (HR 0.65 [95% CI
0.41–1.03]). The risk reduction was
slightly smaller after also adjusting for
intermediate clinical outcomes in model
3 (0.71 [0.44–1.13]).
Other determinants with a significant
predictive value (P , 0.05) for all-cause
mortality in the extended Cox model
(model 3) were CVD (HR 2.70), insulin
medication (HR 2.21), age (HRyear
1.09), self-reported retinopathy (HR
1.88), and detected microalbuminuria
(HR 1.94).
Modifying Effect of Education
A significant interaction effect with SMB
was found for education (P , 0.01 for
all-cause-mortality). Among study par-
ticipants with a low level of education
(#9 years of school), a high level of SMB
was associated with a reduced all-cause
mortality (HR 0.44 [95% CI 0.26–0.74]),
but an opposite picture was seen among
participants with a high level of educa-
tion (.9 years of school); that is, a high
level self-management was associated
with an increased but nonsignificant
risk of all-cause mortality (1.68 [0.76–
3.69]).
Figure 1 graphically displays the raw
Kaplan-Meier survival curves by the
level of self-management for the entire
sample (log-rank test, P = 0.04), as well
as for patients with CVD comorbidity
(P = 0.02), for insulin-treated patients
(P = 0.05), and for patients with a low
level of education (P = 0.02).
Sensitivity Analysis
To identify the dimensions of the self-
management index that mainly contrib-
uted to theobservedeffects,weperformed
separate Cox regression models for each
of the six dimensions, using the basic set
of covariates. Being compliant with
the dimensions “exercising” (HR 0.84
[95% CI 0.60–1.19]), “foot care” (0.85
[0.63–1.14]), “body weight monitoring”
(0.76 [0.54–1.06]), “self-monitoring of
blood glucose” (0.84 [0.62–1.14]), and
“having a diabetes diary” (0.80 [0.56–
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nonsignificant mortality risk, whereas
the dimension “having a diet plan”
(1.20 [0.88–1.63]) was associated
with a nonsignificant elevated mortal-
ity risk. Using the cumulative number
of compliant dimensions as a linear
predictor in the Cox models showed a
borderline significant mortality risk re-
duction of 8–12% for every additional
compliant dimension. Applying a multi-
ple imputation method for missing co-
variates yielded similar HRs and CIs to
the single imputation approach.
CONCLUSIONS
Patient self-management is assumed to
be an important factor for the successful
management of diabetes. To the best of
our knowledge, this study is the first to
analyze the relationships among amulti-
dimensional measure of SMB, interme-
diate outcomes, and mortality. A high
level of patient SMB was associated
with improved glycemic control in the
cross-sectional perspective and pro-
longed life expectancy over a follow-up
period of 12 years.
With a 40% mortality risk reduction,
the predictive value of the multi-
dimensional self-management index
was almost as strong as that seen for
clinical parameters, such as micro-
albuminuria or retinopathy, and was
considerably greater than those of single
self-management dimensions. This find-
ing indicates that different dimensions
of self-management are important for pa-
tients to manage the disease and high-
lights the importance of capturing the
complex structure of SMB in future re-
search. Despite the plausibility of in-
creased life expectancy through better
risk factor tracking (diabetes diary, weight
monitoring), earlier detection of diabe-
tes complications (foot care), or better
glycemic control and fitness (SMBG, ex-
ercising), we actually think that the ef-
fect shown here cannot be attributed
solely to the six dimensions included
in the self-management index. We
rather assume that the index reflects
general multilayered SMB, including be-
havior that we can hardly assess in its
full complexity. Patients who measure
and track their blood glucose level and
risk profile regularly might, for example,
be more likely to have better physician
attendance and medication adherence,
and those habitually monitoring their
weight, feet, and blood glucose level
may in general be more attuned and
sensitive to their body, possibly result-
ing in avoidance, earlier detection, or
better coping with adverse clinical con-
ditions, such as extreme hyperosmolar
periods, hypoglycemia, or (silent) car-
diovascular events.
Because of its multidimensionality,
the accurate assessment of SMB is diffi-
cult (27). Numerous questionnaires and
scales based on different theoretical
frameworks have been developed in
the past (15,16,22,24), and were accom-
panied by controversial discussions
about the rather passive concept of
compliance and themore proactive con-
cepts of adherence, self-care, and self-
management (28–30). The approach of
assessing and defining SMB in this study
also has some limitations. First, the SMB
index that was used does not include
other important dimensions such as
medication adherence or interaction
with health care professionals. Second,
the methodological approach of sum-
marizing quite heterogeneous dimen-
sions of SMB in a global index might be
debatable. Third, one could argue that
the index is a rather pragmatic approach
that cannot be clearly assigned to one of
the mentioned theoretical concepts.
However, this index was already tested
on this sample of patients, contains sim-
ilar dimensions of proactive patient be-
havior as the well-established Summary
of Diabetes Self-Care Activities scale,
and has been shown to include dimen-
sions that do not correlate highly with
each other, a property that was also
found for self-care activity items in
other instruments (23). From our per-
spective, this index can therefore be
considered as a limited, but satisfacto-
rily valid, proxy for themultidimensional
SMB of patients with diabetes.
Furthermore, our results are predom-
inantly consistent with findings from the
few studies on this topic. A positive
cross-sectional association between
self-management measured by the
Summary of Diabetes Self-Care Activi-
ties scale and HbA1c was reported by
Osborn et al. (31). There is also some
growing evidence from randomized
studies that self-care behavior itself
as well as glycemic control can be pos-
itively influenced by active self-
management training and diabetes
education (18,19). Despite a lack of ev-
idence from randomized studies for the
effect of SMB on long-term outcomes,
there is some weak indication that spe-
cific dimensions of SMB are associated
with prolonged life expectancy among di-
abetes patients. A recent meta-analysis
(32) showed that 1-MET/h/day incre-
mentally higher physical activity was
associated with a 9.5% reduction in all-
cause mortality. Based on data from the
multicenter ROSSO (Retrolective Study
Self-Monitoring of Blood Glucose and
Outcome) study, Martin et al. (20) re-
ported in their debatable study that
SMBG reduces the mortality risk
by 50% (33); however, in contrast no ef-
fect on all-cause mortality was found in
the observational prospective Fremantle
Diabetes Study (21). Another large study
Table 3—HRs for all-cause and CVD mortality of multivariate Cox proportional
hazards regression according to the level of diabetes SMB
High vs. low (reference)





HR (95% CI) P value HR (95% CI) P value
All patients 1 0.61* (0.40–0.91) 0.016 0.65 (0.41–1.03) 0.064
2 0.60* (0.40–0.90) 0.013 0.64 (0.41–1.02) 0.061
3 0.62* (0.41–0.94) 0.026 0.71 (0.44–1.13) 0.145
Stratified models
CVD† 1 0.59* (0.37–0.95) 0.031 0.63 (0.38–1.04) 0.068
No CVD 1 0.66 (0.27–1.64) 0.372 0.79 (0.22–2.87) 0.721
Insulin-treated 1 0.57 (0.31–1.07) 0.080 0.53 (0.26–1.12) 0.096
Not insulin-treated 1 0.66 (0.38–1.15) 0.143 0.79 (0.44–1.43) 0.437
Model 1, adjusted for age, sex, education, smoking status, weight status, diabetes treatment,
diabetes duration, history of CVD, retinopathy, neuropathy, nephropathy; Model 2, adjusted for
Model 1 plus medication (antihypertensive, lipid-lowering, and antiplatelet agents); Model 3,
adjusted for Model 2 plus intermediate clinical outcomes (microalbuminuria, polyneuropathy,
PAD, HbA1c, LDL cholesterol, and systolic blood pressure). *P, 0.05. †Patients with previous MI
or stroke.
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based on U.K. general practice records
showed that medication nonadherence
and clinic appointment nonattendance,
two dimensions that may also play an im-
portant role in diabetes self-management,
are associated with 58% and 16–61%, re-
spectively, increased all-cause mortality
(34). Even though the predictor variables
in these studies were different and
not multidimensional, it is possible that
the observed reductions in mortality
were rather attributable to other, unmea-
sured, components of self-management
associated with the tested predictors.
Arnold-Wörner et al. (15) reported in
their study a positive association among
SMB, participation in diabetes educa-
tion, and treatment satisfaction. How-
ever, further analyses of our data
showed that these latter two factors,
as well as general diabetes knowledge,
were not predictive for mortality (re-
sults not shown). This indicates that
SMB, diabetes education, quality of
care, and self-management knowledge
are mutually dependent factors in the
management of diabetes, but that the
actual behavior of patients seems to
be most predictive for long-term health
outcomes.
Our study further shows that the gen-
eral level of education might play an im-
portant role in the context of the
patients’ health behavior and health
outcomes. The data indicate that pa-
tients with a low level of education ben-
efit from good SMB, leading to reduced
mortality, whereas patients with a high
level of education do not profit from it.
Although education is assumed to be
important to transform knowledge into
health behavior and health outcomes,
the great positive effect of SMB among
less educated patients seems to be plau-
sible, because poorly educated patients
might gain greater benefits from basic
health education and its application
than already highly educated and gener-
ally well-performing counterparts (35).
The results of this study highlight the
potential benefit of proper SMB on
patient health. From a translational
perspective, effective and cost-effective
programs that are at the same time
comprehensively implementable and
also able to reach patients with a low
level of education would, therefore, be
highly recommended to improve pa-
tient SMB and, potentially, health out-
comes. As studies showed that peer
support led by clinical staff, peer
coaches, or community health workers
can be an effective low-cost method to
improve SMB, the implementation of
comprehensive peer networks seems
to be a promising extension to classical
structured diabetes education and care
management interventions, which are
rather labor- and cost-intensive (36,37).
In addition to the classic face-to-face
peer group support, the potential of in-
novative telephone/self-management
support or e-mail/web-based support
techniques also need to be considered
(37). Further, most importantly, strate-
gies proven to be effective, cost-
effective, and feasible to implement
should be rapidly adapted by health
Figure 1—Kaplan-Meier survival curves according to the level of SMB. High level of SMB (HL-SMB; dashed line) and low level of SMB (LL-SMB; solid
line). P value was determined by log-rank test.
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care providers, even though adapta-
tions will require changes in the cur-
rent system of care and remuneration
schemes. In addition, from a scientific
perspective, the collection of data
about physician-delivered diabetes ed-
ucation and patient-reported SMB
should, where possible, be routinely as-
sessed and incorporated into electronic
health records, as such data sources are
necessary to enhance population-based
health services research and to strengthen
thepatient-centered perspective in health
care (38,39).
The strengths of this study are
the selection of participants from two
population-based samples originating
from the same study area and the long
follow-up time. Linking a predefined
self-management index that had al-
ready been tested in the same sample
of patientswith a 12-yearmortality follow-
up gave us an exceptional data source to
analyze the association among SMB, ob-
jectively assessed clinical outcomes, and
mortality with a clear a priori hypothe-
sis, while at the same time adjusting for
medical history, medication intake,
treatment regimen, sociodemographic
factors, and clinical parameters. Fur-
ther, the analytic approach of examining
both the cross-sectional association
with intermediate outcomes, as well as
the longitudinal association with mortality
enabled us to gain a better understanding
of potential underlying mechanisms in the
observed relationships.
Our study also had a few limitations
that need to be discussed. Despite the
fact that a high internal consistency was
reported in other KORA studies for dif-
ferent items of treatment adherence
and diabetes knowledge, the validity
and reliability of self-reports in our
study remain unknown. In addition, we
only had information about the level of
self-management at one point in time
and do not know the intraindividual sta-
bility of patient behavior over time,
which is one of the key assumptions
for the plausibility of the observed asso-
ciations. However, we assume that this
limitation is rather likely to have intro-
duced nondifferential bias, resulting in
an underestimation of the observed ef-
fects. Another weakness of the study is
its observational design. Even though
we controlled for most of the variables
that are known to impact mortality
among diabetes patients, we cannot
rule out the possibility of residual con-
founding, nor can we clearly state the
direction of the observed associations
specifically in the cross-sectional per-
spective (40). Unmeasured dimensions
like patient expectations, self-efficacy,
general quality of care, and socioeco-
nomic status possibly interacted with
self-management and life expectancy.
And particular aspects of mental health,
such as depression, which are known to
be predictive for mortality and are gen-
erally associated with health behavior,
might have biased effect estimates. It
also has to be emphasized that the num-
ber of participants was limited and that
incomplete data on covariates had to be
imputed to avoid a further reduction in
power. Whereas our sensitivity analyses
indicated that the latter point is rather
unproblematic, the relatively small sam-
ple size prohibited a more detailed and
stratified analysis of the data and re-
stricted the power of our models. Fi-
nally, the sampling of participants from
two different population-based data
sources yielded an over-representation
ofmenwith previousmyocardial events,
which limits the external validity and
generalizability of our results.
Despite its limitations, this study indi-
cates that a high level of self-management
is associated with prolonged life expec-
tancy. Further refinement of current
self-management measures and the in-
clusion of these instruments in long-
term observational studies, routinely
assessed health care records, and ran-
domized controlled trials are necessary
to improve the understanding of pa-
tients’ active role in diseasemanagement
and to derive practical implications
for future directions in diabetes self-
management education.
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